20. Eucrisa


Active ingredient: crisaborole
Disease: eczema (atopic dermatitis)
Peak sales estimate: $2 billion
Approved: Dec. 14
Company: Pfizer

The Scoop: With Eucrisa’s early approval, Pfizer squeaked across the finish line with barely two weeks of 2016 to go. The Big Pharma acquired the drug—which was OK’d more than three weeks before its January 2017 PDUFA date—in its $4.5 billion buyout of Anacor Pharmaceuticals. Eucrisa, a phosphodiesterase 4 (PDE-4) inhibitor, is indicated for people aged two years and older who have mild to moderate atopic dermatitis. It was tested in more than 1,500 people, besting placebo in clearing up eczema symptoms in 28 days. It is the first new treatment to be approved for the skin condition in 15 years. And with the vast majority—90%—of people with atopic dermatitis having a mild-to-moderate form of the condition, Eucrisa stands to fetch up to $2 billion in sales. -- Amirah Al Idrus

20. Eucrisa

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.